NCT06646354

To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel Group, Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

• Status: Enrolling By Invitation
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 125 (estimated)
• Sponsor: Hyundai Pharm · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Detailed description

This trial is a phase 3 study to evaluate the efficacy and safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia. This is multi-center, double-blind, Active-controlled, parallel-group, phase 3 study.

Conditions

• Hypertension
• Primary Hypercholesterolaemia

Interventions

Type	Name	Description
DRUG	Ezetimibe/Rosuvastatin/Candesartan/Amlodipine	PO, QD, 8 weeks
DRUG	Candesartan/Amlodipine	PO, QD, 8 weeks
DRUG	Candesartan/Rosuvastatin/Ezetimibe	PO, QD, 8 weeks

Timeline

• Start date: 2025-04-22
• Primary completion: 2025-05-19
• Completion: 2028-12-31
• First posted: 2024-10-17
• Last updated: 2025-05-22

Locations

1 site across 1 country: South Korea